After hours:
Chart Events
Performance Outlook
| Previous Close | 14.89 |
| Open | 15.81 |
| Bid | 15.10 x 900 |
| Ask | 15.23 x 800 |
| Day's Range | 15.06 - 16.36 |
| 52 Week Range | 2.00 - 18.03 |
| Volume | |
| Avg. Volume | 2,067,036 |
| Market Cap | 770.038M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.82 |
| Earnings Date | May 09, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.38 |
- Motley Fool
Why Shares of 89bio Soared This Week
Shares of clinical-stage biopharmaceutical company 89bio (NASDAQ: ETNB) were up 36.2% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The healthcare company, which focuses on therapies to treat liver and cardio-metabolic diseases, released positive news regarding its lead therapy, pegozafermin. In a phase 2b study, a weekly 44-milligram dose and a weekly 30-mg dose of the drug both met the primary endpoints in treating patients with nonalcoholic steatohepatitis (NASH), a disease that causes the liver to swell and be damaged.
- GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering
- GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc
